- Home
- MGRX vs APVO Comparison
MGRX vs APVO Comparison
Compare MGRX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- APVO
- Stock Information
- Founded
- MGRX 2021
- APVO 2016
- Country
- MGRX United States
- APVO United States
- Employees
- MGRX N/A
- APVO N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- APVO Health Care
- Exchange
- MGRX Nasdaq
- APVO Nasdaq
- Market Cap
- MGRX 12.3M
- APVO 5.4M
- IPO Year
- MGRX 2023
- APVO N/A
- Fundamental
- Price
- MGRX $4.04
- APVO $2.38
- Analyst Decision
- MGRX
- APVO Strong Buy
- Analyst Count
- MGRX 0
- APVO 1
- Target Price
- MGRX N/A
- APVO $296.00
- AVG Volume (30 Days)
- MGRX 79.8K
- APVO 47.1K
- Earning Date
- MGRX 03-31-2025
- APVO 05-07-2025
- Dividend Yield
- MGRX N/A
- APVO N/A
- EPS Growth
- MGRX N/A
- APVO N/A
- EPS
- MGRX N/A
- APVO N/A
- Revenue
- MGRX $755,000.00
- APVO N/A
- Revenue This Year
- MGRX N/A
- APVO N/A
- Revenue Next Year
- MGRX N/A
- APVO N/A
- P/E Ratio
- MGRX N/A
- APVO N/A
- Revenue Growth
- MGRX 52.20
- APVO N/A
- 52 Week Low
- MGRX $2.07
- APVO $2.35
- 52 Week High
- MGRX $16.80
- APVO $207.35
- Technical
- Relative Strength Index (RSI)
- MGRX 48.24
- APVO 28.55
- Support Level
- MGRX $3.59
- APVO $3.02
- Resistance Level
- MGRX $5.33
- APVO $4.00
- Average True Range (ATR)
- MGRX 0.58
- APVO 0.27
- MACD
- MGRX -0.09
- APVO -0.03
- Stochastic Oscillator
- MGRX 26.07
- APVO 1.58
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.